TITLE

Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists

AUTHOR(S)
Scislowski, P W D; Tozzo, E; Zhang, Y; Phaneuf, S; Prevelige, R; Cincotta, A H
PUB. DATE
April 1999
SOURCE
International Journal of Obesity & Related Metabolic Disorders;Apr1999, Vol. 23 Issue 4, p425
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: We previously reported that a two week treatment with SKF 38393 (SKF, a dopamine D1 receptor agonist), plus bromocriptine (BC, a dopamine D2 receptor agonist) acted synergistically to normalize hyperphagia, body fat, hyperglycaemia and hyperlipidaemia in ob/ob mice. The present study further investigates the biochemical mechanisms triggered by this drug treatment. DESIGN: Six week old female C57BL/6J ob/ob mice were divided into three groups and treated for two weeks with either BC and SKF, vehicle (control), or vehicle and pair fed to match the drug-treated group’s daily food intake. RESULTS: BC/SKF treatment reduced food consumption by 55%, and treated mice weighed less than either pair fed or ad libitum fed controls after two weeks of treatment. Moreover, oxygen consumption was increased by 2.4-fold and the respiratory quotient (RQ) decreased from 1.23 to 0.96 (indicating a reduction in de novo lipogenesis) by drug treatment relative to ad libitum fed controls, but these parameters were unaffected by pair feeding control mice. The treatment also reduced blood glucose and free fatty acids (FFA) relative to pair fed and ad libitum fed controls. BC/SKF treatment (but not pair feeding) concurrently reduced lipolysis, lipogenic enzyme activities and hepatic gluconeogenic enzyme activities. Treatment also increased hepatic concentrations of glycogen and xylulose-5-phosphate (X-5-P), a key stimulator of glycolysis. Finally, BC/SKF, but not pair feeding, reduced the circulating concentrations of thyroxine and corticosterone, two hormones known to increase lipolysis, lipogenesis and hyperglycaemia. Drug treatment also increased serum dehydroepiandrosterone (DHEA) sulfate concentrations, an inhibitor of body fat store accumulation. CONCLUSION: These findings demonstrate that BC/SKF treatment not only normalizes hyperphagia of ob/ob mice, but also redirects several metabolic and endocrine activities, independent of its effects on...
ACCESSION #
8853017

 

Related Articles

  • Combination of two different dopamine agonists in the management of Parkinson's disease. Stocchi, F.; Berardelli, A.; Vacca, L.; Thomas, A.; De Pandis, M.F.; Modugno, N.; Valente, M.; Ruggieri, S. // Neurological Sciences;Sep2002 Supplement 2, Vol. 23, pS115 

    An alternative approach to the symptomatic treatment of parkinsonian patients with and without motor fluctuations is to use dual dopamine agonists. The aim of this study was to investigate the symptomatic effect of administrating a second dopamine agonist to parkinsonian patients already...

  • Is cabergoline a better drug to inhibit lactation in patients with psychotic symptoms? Pertegaz, Immaculada Baeza; alberdi, Jose Manuel Goikolea; Rodon, Eduard Parellada // Journal of Psychiatry & Neuroscience;Jan2002, Vol. 27 Issue 1, p54 

    Evaluates the use of the dopamine agonist, cabergoline, to inhibit lactation in patients with psychotic symptoms. Higher specificity and affinity for the dopamine D[sub 2] receptor and longer lasting suppression of prolactin release of the compound than bromocriptine; Adverse effects of the...

  • Ontogeny of the behavioral response to dopamine agonists after chronic cocaine. Bowman, B. P.; Blatt, Brian; Kuhn, Cynthia M. // Psychopharmacology;1997, Vol. 129 Issue 2, p121 

    Abstract The behavioral response to separate and combined administration of dopamine D[sub 1] and D[sub 2] receptor agonists was assessed acutely and after chronic cocaine exposure (30 mg/kg SC b.i.d, for 5 days) in infant (PND[sub 11] and weanling (PND[sub 20]) rats. In infants, quinpirole...

  • Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning. Feifel, David; Priebe, Kristianne; Johnstone-Miller, Elizabeth; Morgan, Christopher J. // Psychopharmacology;2002, Vol. 162 Issue 2, p138 

    Presents a study to investigate whether dopamine agonist-induced disruption of prepulse inhibition could be conditioned and whether repeated administration of dopamine agonists would produce sensitization to dopamine agonist-induced disruption of prepulse inhibition. Methods; Results;...

  • Pergolide Off the Market, Heart Disease Risk. Elliott, William T. // Internal Medicine Alert;5/15/2007, Vol. 29 Issue 9, p2 

    The article reports on the withdrawal of pergolide, a dopamine agonist used for the treatment of Parkinson's disease, from the market after reports of serious valvular heart disease linked with the drug.

  • Clinical Pharmacokinetics of Cabergoline. Dotto, Paolo Del; Bonuccelli, Ubaldo // Clinical Pharmacokinetics;May2003, Vol. 42 Issue 7, p633 

    Cabergoline is a synthetic ergoline dopamine agonist with a high affinity for D[sub 2] receptors indicated for use in both early and advanced Parkinson’s disease and in hyperprolactinaemic disorders. Following oral administration, peak plasma concentrations of cabergoline are reached...

  • Bromocriptine/cabergoline.  // Reactions Weekly;7/9/2011, Issue 1359, p12 

    The article describes three cases of male patients with macroprolactinomas who developed impulse control disorders (ICDs) while undergoing dopamine agonist (DA) therapy with bromocriptine and cabergoline.

  • Managing prolactinomas during pregnancy. Hussain Almalki, Mussa; Alzahrani, Saad; Alshahrani, Fahad; Alsherbeni, Safia; Almoharib, Ohoud; Aljohani, Naji; Almagamsi, Abdurahman // Frontiers in Endocrinology;May2015, Vol. 6, p1 

    Prolactinomas are the most prevalent functional benign pituitary tumors due to a pituitary micro- or macroadenoma. The majority of patients presents with infertility and gonadal dysfunction. A dopamine agonist (DA) (bromocriptine or cabergoline) is the treatment of choice that can normalize...

  • Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma. Demartini, Benedetta; Ricciardi, Lucia; Ward, Alexandra; Edwards, Mark J. // Journal of Neurology, Neurosurgery & Psychiatry;Apr2014, Vol. 85 Issue 4, p471 

    No abstract available.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics